IP Library Patent Application 18257479
Patent Application
App. No. 18/257,479

A METHOD FOR EVALUATING THE PRO-OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/257,479
Abstract

The present invention relates to a method of evaluating the pro- or anti convulsive properties of test compounds that is both streamlined and is capable of providing a clear indication for the selection of candidate compounds during preclinical assessment.

Claims (16)

1 . A method of assessing the pro- or anti-convulsant properties of a test compound comprising the following steps:

a. dosing a number of animals with one of either a vehicle, the test compound or a positive control compound;

b. determining if the animals produce a tonic hind limb extensor convulsion at a defined period of time post-dose from a single electroshock at a defined current;

c. decreasing or increasing the defined current if the preceding animal did or did not produce tonic hind limb extensor convulsion, respectively and

d. collecting CC 50 values for the treated animals;

characterized in that the number of animals used is at least 6.

2 . The method according to claim 1 , wherein the number of animals used is no more than 11.

3 . The method according to claim 1 , wherein the current of the electroshock is decreased or increased in a logarithmic scale.

4 . The method according to claim 1 , wherein the defined period of time post-dose is at least 15 minutes.

5 . The method according to claim 1 , wherein the defined period of time post-dose is about 30 minutes.

6 . The method according to claim 1 , wherein the defined period of time post-dose is 120 minutes.

7 . The method according to claim 1 , wherein the positive control compound is diazepam.

8 . The method according to claim 1 , wherein the positive control compound is sodium valproate.

9 . The method according to claim 1 , wherein the animal used is a mouse.

10 . The method according to claim 1 , wherein the animal used is a rat.

11 . The method according to claim 1 , wherein the animal used is a pig.

Assignments (3)
CHANGE OF NAME Recorded May 19, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071152/0576 →
SECURITY AGREEMENT Recorded Jul 26, 2024
From: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED); CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: TSE, KAREN KA-YEN; GRAY, ROYSTON ANTHONY
To: GW RESEARCH LIMITED
Reel/Frame 065559/0605 →